cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.5281/zenodo.3706695
title: Dataset related to article "Re-irradiation for recurrent glioma: outcome evaluation, toxicity and prognostic factors assessment. A multicenter study of the Radiation Oncology Italian Association (AIRO)"

description: Abstract INTRODUCTION: The prognosis of glioma is dismal, and almost all patients relapsed. At recurrence time, several treatment options are considered, but to date there is no a standard of care. The Neurooncology Study Group of the Italian Association of Radiation Oncology (AIRO) collected clinical data regarding a large series of recurrent glioma patients who underwent re-irradiation (re-RT) in Italy. METHODS: Data regarding 300 recurrent glioma patients treated from May 2002 to November 2017, were analyzed. All patients underwent re-RT. Surgical resection, followed by re-RT with concomitant and adjuvant chemotherapy was performed. Clinical outcome was evaluated by neurological examination and brain MRI performed, 1 month after radiation therapy and then every 3 months. RESULTS: Re-irradiation was performed at a median interval time (IT) of 16 months from the first RT. Surgical resection before re-RT was performed in 19% of patients, concomitant temozolomide (TMZ) in 16.3%, and maintenance chemotherapy in 29%. Total doses ranged from 9 Gy to 52.5 Gy, with a median biological effective dose of 43 Gy. The median, 1, 2 year OS were 9.7 months, 41% and 17.7%. Low grade glioma histology (p ≪ 0.01), IT &gt; 12 months (p = 0.001), KPS &gt; 70 (p = 0.004), younger age (p = 0.001), high total doses delivered (p = 0.04), and combined treatment performed (p = 0.0008) were recorded as conditioning survival. CONCLUSION: our data underline re-RT as a safe and feasible treatment with limited rate of toxicity, and a combined ones as a better option for selected patients. The identification of a BED threshold able to obtain a greater benefit on OS, can help in designing future prospective studies.
DOI: 10.7910/dvn/1vemis/oqk2fr
title: T6_WT_CD31_1.5.tif

description: :unav
DOI: 10.7910/dvn/1vemis/pxd6jj
title: T16_WT_SMA_2.7.tif

description: :unav
DOI: 10.7910/dvn/1vemis/uwxv92
title: T21_WT_SMA_2.18.tif

description: :unav
DOI: 10.7910/dvn/1vemis/4ye7bq
title: T20_WT_SMA_1.2.tif

description: :unav
DOI: 10.7910/dvn/1vemis/mcp1ob
title: T2_KO_SMA_1.7.tif

description: :unav
DOI: 10.7910/dvn/1vemis/qshwal
title: T2_KO_SMA_1.4.tif

description: :unav
DOI: 10.7910/dvn/1vemis/riel7s
title: T13_KO_CD31_2.8.tif

description: :unav
DOI: 10.7910/dvn/1vemis/4i7ria
title: T20_WT_CD31_3.12.tif

description: :unav
DOI: 10.7910/dvn/1vemis/58aybr
title: T16_WT_SMA_1.7.tif

description: :unav
DOI: 10.7910/dvn/1vemis/fnovzk
title: T13_KO_CD31_1.8.tif

description: :unav
DOI: 10.7910/dvn/1vemis/q6f6dc
title: T18_WT_SMA_2.10.tif

description: :unav
DOI: 10.7910/dvn/1vemis/rls9ob
title: T20_WT_SMA_1.6.tif

description: :unav
DOI: 10.7910/dvn/1vemis/1pmbgq
title: T14_KO_SMA_2.12.tif

description: :unav
DOI: 10.7910/dvn/1vemis/58hhz0
title: T14_KO_SMA_1.11.tif

description: :unav
DOI: 10.7910/dvn/1vemis/ejepwy
title: T6_WT_SMA_2.3.tif

description: :unav
DOI: 10.7910/dvn/1vemis/dc7ore
title: T21_WT_CD31_1.27.tif

description: :unav
DOI: 10.7910/dvn/1vemis/krivic
title: T18_WT_SMA_2.4.tif

description: :unav
DOI: 10.7910/dvn/1vemis/vqqvtc
title: T14_KO_CD31_2.11.tif

description: :unav
DOI: 10.7910/dvn/1vemis/xd2sov
title: T13_KO_SMA_1.19.tif

description: :unav
DOI: 10.7910/dvn/1vemis/0elnym
title: T21_WT_SMA_2.27.tif

description: :unav
DOI: 10.7910/dvn/1vemis/ssuizo
title: T12_WT_SMA_2.5.tif

description: :unav
DOI: 10.7910/dvn/1vemis/andfus
title: T1_WT_SMA_3.5.tif

description: :unav
DOI: 10.7910/dvn/1vemis/bwd1xz
title: T16_WT_CD31_2.32.tif

description: :unav
DOI: 10.7910/dvn/1vemis/trb67u
title: T18_WT_SMA_2.22.tif

description: :unav
DOI: 10.7910/dvn/1vemis/epw2or
title: T20_WT_CD31_3.2.tif

description: :unav
DOI: 10.7910/dvn/1vemis/jqm6nj
title: T21_WT_SMA_2.20.tif

description: :unav
DOI: 10.7910/dvn/1vemis/jwnym5
title: T6_WT_SMA_1.7.tif

description: :unav
DOI: 10.7910/dvn/1vemis/uq2rql
title: T2_KO_SMA_2.2.tif

description: :unav
DOI: 10.7910/dvn/1vemis/fdl2ip
title: T18_WT_SMA_1.15.tif

description: :unav
DOI: 10.7910/dvn/1vemis/gnf636
title: T12_WT_SMA_2.11.tif

description: :unav
DOI: 10.7910/dvn/1vemis/w3ikfm
title: T21_WT_CD31_1.26.tif

description: :unav
DOI: 10.7910/dvn/1vemis/zfxlbp
title: T18_WT_CD31_1.6.tif

description: :unav
DOI: 10.7910/dvn/1vemis/bq4kgc
title: T6_WT_SMA_2.15.tif

description: :unav
DOI: 10.7910/dvn/1vemis/r5n5yv
title: T14_KO_CD31_1.30.tif

description: :unav
DOI: 10.7910/dvn/1vemis/cn27hj
title: T16_WT_SMA_1.32.tif

description: :unav
DOI: 10.7910/dvn/1vemis/xaf9hd
title: T16_WT_SMA_1.5.tif

description: :unav
DOI: 10.7910/dvn/1vemis/npikbp
title: T16_WT_CD31_2.22.tif

description: :unav
DOI: 10.7910/dvn/1vemis/q8wqsp
title: T2_KO_SMA_2.3.tif

description: :unav
DOI: 10.7910/dvn/1vemis/uuj5uq
title: T14_KO_SMA_1.26.tif

description: :unav
DOI: 10.7910/dvn/1vemis/amnosp
title: T16_WT_SMA_2.21.tif

description: :unav
DOI: 10.7910/dvn/1vemis/dwkba3
title: T14_KO_CD31_1.8.tif

description: :unav
DOI: 10.7910/dvn/1vemis/lkw7vj
title: T21_WT_CD31_2.8.tif

description: :unav
DOI: 10.7910/dvn/1vemis/ewv3oe
title: T20_WT_CD31_1.3.tif

description: :unav
DOI: 10.7910/dvn/1vemis/hapxxe
title: T18_WT_CD31_1.5.tif

description: :unav
DOI: 10.7910/dvn/1vemis/jgnvqm
title: T21_WT_SMA_1.10.tif

description: :unav
DOI: 10.17037/data.00001623
title: Clinical codelist - Congenital malformation codes

description: Read codes for congenital malformations; Codes are categorized according to the EUROCAT classification system and minor malformations are noted.
DOI: 10.7910/dvn/1vemis/oc7gif
title: T13_KO_SMA_2.5.tif

description: :unav
DOI: 10.7910/dvn/1vemis/t6ohw6
title: T6_WT_CD31_2.1.tif

description: :unav
DOI: 10.7910/dvn/1vemis/ebrutc
title: T21_WT_SMA_1.2.tif

description: :unav
DOI: 10.7910/dvn/1vemis/ckepre
title: T13_KO_SMA_2.4.tif

description: :unav
DOI: 10.7910/dvn/1vemis/vryzkt
title: T2_KO_SMA_1.8.tif

description: :unav
DOI: 10.7910/dvn/1vemis/pftjlb
title: T14_KO_SMA_1.40.tif

description: :unav
DOI: 10.17037/data.00001626
title: Clinical codelist - Influenza vaccination codes

description: Read codes for Influenza vaccination
DOI: 10.17037/data.00001625
title: HES procedures codelist - Congenital malformation codes

description: OPCS-4 codes for congenital malformations; Codes are categorized according to the EUROCAT classification system and minor malformations are noted.
DOI: 10.17037/data.00001627
title: Immunisation codelist - Influenza vaccination codes

description: Immunisation codes for influenza vaccination.
DOI: 10.17037/data.00001628
title: Therapy codelist - Influenza vaccination codes

description: Product codes for influenza vaccination
DOI: 10.34622/datarepositorium/rjeyji/ilgoqx
title: Consentimento Informado_EntJovens.pdf

description: Termo de consentimento informado para participação em entrevista (Percursos Académicos Atípicos)
DOI: 10.34622/datarepositorium/rjeyji/tsq21b
title: Consentimento Informado_EntJovens_EE.pdf

description: Termo de autorização para participação de menor em entrevista (Percursos Académicos Atípicos)
DOI: 10.34622/datarepositorium/rjeyji/htftnp
title: Informação participantes_EntJovens.pdf

description: Informação sobre o projeto EDUPLACES para Jovens entrevistados no âmbito do Marco 4 - Percursos Académicos Atípicos
DOI: 10.34622/datarepositorium/rjeyji/knmt62
title: Guião para a entrevista a Jovens com Percursos Académicos Atípicos.pdf

description: Guião para a entrevista a Jovens com Percursos Académicos Atípicos
DOI: 10.34622/datarepositorium/rjeyji/yaskyf
title: Quadro de síntese de caracterização PAA.pdf

description: Quadro-síntese de caracterização dos quinze jovens entrevistados no âmbito do Marco 4 - Percursos Académicos Atípicos
DOI: 10.5281/zenodo.3706781
title: Dataset related to article "Surgery Followed by Hypofractionated Radiosurgery on the Tumor Bed in Oligometastatic Patients With Large Brain Metastases. Results of a Phase 2 Study"

description: PURPOSE: This prospective phase II study assessed safety and feasibility of surgery followed by hypofractionated radiosurgery (HSRS) on the tumor bed in oligometastatic patients with single large brain metastases (BMs). METHODS AND MATERIALS: Between June 2015 and May 2018, 101 patients were enrolled. Oligometastatic disease was defined by a maximum of 5 extracranial metastatic lesions. HSRS was performed within 1 month of surgery and consisted of 30 Gy in 3 fractions. Local control, occurrence of new BMs, overall survival, and treatment-related toxicities were assessed. RESULTS: At a median follow-up time of 26 months, local recurrence occurred in 6 patients (5.9%). Six-month, 1-year, and 2-year local control rates were 100%, 98.9% ± 1.1%, and 85.9% ± 0.6%, respectively. New BMs occurred in 39 patients (38.6%); median brain distant progression time and 6-month, 1-year, and 2-year brain distant progression rates were 39 months (95% CI, 19-39 months), 17% ± 3.7%, 31.4% ± 4.8%, and 42.5% ± 5.9%, respectively. At the last observation time, 50 patients (49.5%) were alive and 51 (50.5%) were dead; 10 patients died owing to neurologic causes and 40 as a result of systemic progression. Median overall survival time and 6-month, 1-year, and 2-year overall survival rates were 22 months (95% CI, 20-30 months), 95% ± 2.1%, 81.9% ± 3.8%, and 46.6% ± 6%, respectively. Infratentorial site, residual tumor volume, longer interval time between primary diagnosis and occurrence of BMs, and oligometastatic disease status significantly influenced outcome. Grade 2 to 3 radionecrosis occurred in 26 patients. Neurocognitive functions remained stable or, in some cases, improved. CONCLUSIONS: Surgery followed by HSRS on the tumor bed is a safe and effective approach, affording good brain control with acceptable toxicities. As for extracranial metastatic sites, patients with BMs can benefit from local ablative treatment in the context of an oligometastatic disease.
DOI: 10.5281/zenodo.3706780
title: Dataset related to article "Surgery Followed by Hypofractionated Radiosurgery on the Tumor Bed in Oligometastatic Patients With Large Brain Metastases. Results of a Phase 2 Study"

description: PURPOSE: This prospective phase II study assessed safety and feasibility of surgery followed by hypofractionated radiosurgery (HSRS) on the tumor bed in oligometastatic patients with single large brain metastases (BMs). METHODS AND MATERIALS: Between June 2015 and May 2018, 101 patients were enrolled. Oligometastatic disease was defined by a maximum of 5 extracranial metastatic lesions. HSRS was performed within 1 month of surgery and consisted of 30 Gy in 3 fractions. Local control, occurrence of new BMs, overall survival, and treatment-related toxicities were assessed. RESULTS: At a median follow-up time of 26 months, local recurrence occurred in 6 patients (5.9%). Six-month, 1-year, and 2-year local control rates were 100%, 98.9% ± 1.1%, and 85.9% ± 0.6%, respectively. New BMs occurred in 39 patients (38.6%); median brain distant progression time and 6-month, 1-year, and 2-year brain distant progression rates were 39 months (95% CI, 19-39 months), 17% ± 3.7%, 31.4% ± 4.8%, and 42.5% ± 5.9%, respectively. At the last observation time, 50 patients (49.5%) were alive and 51 (50.5%) were dead; 10 patients died owing to neurologic causes and 40 as a result of systemic progression. Median overall survival time and 6-month, 1-year, and 2-year overall survival rates were 22 months (95% CI, 20-30 months), 95% ± 2.1%, 81.9% ± 3.8%, and 46.6% ± 6%, respectively. Infratentorial site, residual tumor volume, longer interval time between primary diagnosis and occurrence of BMs, and oligometastatic disease status significantly influenced outcome. Grade 2 to 3 radionecrosis occurred in 26 patients. Neurocognitive functions remained stable or, in some cases, improved. CONCLUSIONS: Surgery followed by HSRS on the tumor bed is a safe and effective approach, affording good brain control with acceptable toxicities. As for extracranial metastatic sites, patients with BMs can benefit from local ablative treatment in the context of an oligometastatic disease.
DOI: 10.17037/data.00001630
title: Codelists for: "Identifying major congenital malformations in anonymised UK electronic health records: the value of primary care, hospital admissions and mortality data"
DOI: 10.5281/zenodo.3706803
title: Accuracy of panoramic radiograph for diagnosing periodontitis comparing to clinical examination

description: Accuracy of panoramic radiograph for diagnosing periodontitis comparing to clinical examination dataset
DOI: 10.5281/zenodo.3706804
title: Accuracy of panoramic radiograph for diagnosing periodontitis comparing to clinical examination

description: Accuracy of panoramic radiograph for diagnosing periodontitis comparing to clinical examination dataset
DOI: 10.5281/zenodo.3706806
title: Link to dataset related to article "Not only cancer: the long non-coding RNA MALAT1 affects the repertoire of alternatively spliced transcripts and circular RNAs in multiple sclerosis."

description: Long non-coding RNAs (lncRNAs) are post-transcriptional and epigenetic regulators, whose implication in neurodegenerative and autoimmune diseases remains poorly understood. We analyzed publicly available microarray data sets to identify dysregulated lncRNAs in multiple sclerosis (MS), a neuroinflammatory autoimmune disease. We found a consistent upregulation in MS of the lncRNA MALAT1 (2.7-fold increase; meta-analysis, P = 1.3 × 10-8; 190 cases, 182 controls), known to regulate alternative splicing (AS). We confirmed MALAT1 upregulation in two independent MS cohorts (1.5-fold increase; P &lt; 0.01; 59 cases, 50 controls). We hence performed MALAT1 overexpression/knockdown in cell lines, demonstrating that its modulation impacts on endogenous expression of splicing factors (HNRNPF and HNRNPH1) and on AS of MS-associated genes (IL7R and SP140). Minigene-based splicing assays upon MALAT1 modulation recapitulated IL7R and SP140 isoform unbalances observed in patients. RNA-sequencing of MALAT1-knockdown Jurkat cells further highlighted MALAT1 role in splicing (approximately 1100 significantly-modulated AS events) and revealed its contribution to backsplicing (approximately 50 differentially expressed circular RNAs). Our study proposes a possible novel role for MALAT1 dysregulation and the consequent AS alteration in MS pathogenesis, based on anomalous splicing/backsplicing profiles of MS-relevant genes.
DOI: 10.5281/zenodo.3706805
title: Link to dataset related to article "Not only cancer: the long non-coding RNA MALAT1 affects the repertoire of alternatively spliced transcripts and circular RNAs in multiple sclerosis."

description: Long non-coding RNAs (lncRNAs) are post-transcriptional and epigenetic regulators, whose implication in neurodegenerative and autoimmune diseases remains poorly understood. We analyzed publicly available microarray data sets to identify dysregulated lncRNAs in multiple sclerosis (MS), a neuroinflammatory autoimmune disease. We found a consistent upregulation in MS of the lncRNA MALAT1 (2.7-fold increase; meta-analysis, P = 1.3 × 10-8; 190 cases, 182 controls), known to regulate alternative splicing (AS). We confirmed MALAT1 upregulation in two independent MS cohorts (1.5-fold increase; P &lt; 0.01; 59 cases, 50 controls). We hence performed MALAT1 overexpression/knockdown in cell lines, demonstrating that its modulation impacts on endogenous expression of splicing factors (HNRNPF and HNRNPH1) and on AS of MS-associated genes (IL7R and SP140). Minigene-based splicing assays upon MALAT1 modulation recapitulated IL7R and SP140 isoform unbalances observed in patients. RNA-sequencing of MALAT1-knockdown Jurkat cells further highlighted MALAT1 role in splicing (approximately 1100 significantly-modulated AS events) and revealed its contribution to backsplicing (approximately 50 differentially expressed circular RNAs). Our study proposes a possible novel role for MALAT1 dysregulation and the consequent AS alteration in MS pathogenesis, based on anomalous splicing/backsplicing profiles of MS-relevant genes.
DOI: 10.5519/qd.kt23q248
title: Query on the Natural History Museum Data Portal (data.nhm.ac.uk) (30 records)
DOI: 10.7910/dvn/wknptm/1cpbkd
title: Supplementary Table S1 Cladode temperatures.tab

description: :unav
DOI: 10.7910/dvn/wknptm
title: Replication Data for: Resource allocation among cladodes of Opuntia robusta from the central-eastern mexico

description: To test whether the type of fabric used to shade cladodes had an effect on temperature near cladode surface, we performed an experiment: we measured the temperature on the surface of uncovered cladodes, and of cladodes covered with black cotton coarse fabric or with black cotton coarse fabric lined with white tulle, for twelve hours (8 a.m. through 7 p.m.). The paired t-test showed significant differences between the temperatures of non-covered cladodes and cladodes covered with black cotton coarse fabric (t = 2.88, P = 0.015), and non-significant differences between the temperatures of non-covered cladodes and cladodes covered with black cotton coarse fabric lined with white tulle (t = 0.84, P = 0.42): we used the black cotton coarse fabric lined with white tulle for field experiment
DOI: 10.17037/data.00001624
title: HES diagnosis codelist - Congenital malformation codes

description: ICD-10 codes for congenital malformations; Codes are categorized according to the EUROCAT classification system and minor malformations are noted.
DOI: 10.5281/zenodo.3706821
title: Dataset related to article "Predictive Factors for Response and Survival in a Cohort of Oligometastatic Patients Treated With Stereotactic Body Radiation Therapy."

description: PURPOSE: This study evaluated patients, treatment, or disease characteristics that could predict response to stereotactic body radiation therapy (SBRT) and survival in a database of patients with oligometastatic disease from different solid tumors. METHODS AND MATERIALS: Patients treated with SBRT for oligometastatic disease between 2014 and 2015 were included. Patients were defined as oligometastatic if they were affected by a maximum of 5 active lesions in 3 different sites. They had to be treated with SBRT with radical intent. RESULTS: The study included 358 patients. With a median follow-up of 31.83 months, local control at 6 and 24 months was 94.6% and 78.9%, respectively. Distant progression was recorded in 279 patients (77.9%). Progression-free survival at 6 and 24 months was 66.1% and 18.4%, respectively. At last follow-up, 195 patients (54.5%) were still alive in 59 cases with no evidence of disease. The median overall survival (OS) was 34.7 months (95% confidence interval, 29.66-43.83). OS at 6 and 24 months was 96.07% and 63.57%, respectively. On multivariable analysis, the presence of lung metastases (hazard ratio [HR], 0.50 [0.33-0.75]; P = .001) and nodal metastases (HR, 0.44 [0.24-0.78]; P = .005) was related to longer OS. Primary lung cancer (HR, 1.89 [1.14-3.13]; P = .013), increasing age (HR, 1.02 [1.01-1.04]; P = .002), and the presence of metastatic sites other than the irradiated ones (HR, 2.19 [1.39-3.43]; P = .001) were all independent predictors of shorter OS. Local response was associated with OS. CONCLUSIONS: SBRT for patients with oligometastatic disease is effective. Local response is strongly correlated with patients'' prognosis, also underlying its relevance in a metastatic setting.
DOI: 10.5281/zenodo.3706820
title: Dataset related to article "Predictive Factors for Response and Survival in a Cohort of Oligometastatic Patients Treated With Stereotactic Body Radiation Therapy."

description: PURPOSE: This study evaluated patients, treatment, or disease characteristics that could predict response to stereotactic body radiation therapy (SBRT) and survival in a database of patients with oligometastatic disease from different solid tumors. METHODS AND MATERIALS: Patients treated with SBRT for oligometastatic disease between 2014 and 2015 were included. Patients were defined as oligometastatic if they were affected by a maximum of 5 active lesions in 3 different sites. They had to be treated with SBRT with radical intent. RESULTS: The study included 358 patients. With a median follow-up of 31.83 months, local control at 6 and 24 months was 94.6% and 78.9%, respectively. Distant progression was recorded in 279 patients (77.9%). Progression-free survival at 6 and 24 months was 66.1% and 18.4%, respectively. At last follow-up, 195 patients (54.5%) were still alive in 59 cases with no evidence of disease. The median overall survival (OS) was 34.7 months (95% confidence interval, 29.66-43.83). OS at 6 and 24 months was 96.07% and 63.57%, respectively. On multivariable analysis, the presence of lung metastases (hazard ratio [HR], 0.50 [0.33-0.75]; P = .001) and nodal metastases (HR, 0.44 [0.24-0.78]; P = .005) was related to longer OS. Primary lung cancer (HR, 1.89 [1.14-3.13]; P = .013), increasing age (HR, 1.02 [1.01-1.04]; P = .002), and the presence of metastatic sites other than the irradiated ones (HR, 2.19 [1.39-3.43]; P = .001) were all independent predictors of shorter OS. Local response was associated with OS. CONCLUSIONS: SBRT for patients with oligometastatic disease is effective. Local response is strongly correlated with patients'' prognosis, also underlying its relevance in a metastatic setting.
DOI: 10.5281/zenodo.3706440
title: Synthetic model parameters for the comparison between an equivalent source and a minimum curvature interpolator of aeromagnetic data

description: Parameters of the synthetic case used in Gavazzi et al. (submitted)[1] FILES (ASCII FORMAT) param.txt<br> General parameters of the geomagnetic field<br> Incl. inclination of the geomagnetic field<br> decl. declination of the geomagnetic field sources.txt<br> Localization and magnetization of the simulated sources<br> xs x-position of the sources (in m)<br> ys y-position of the sources (in m)<br> zs z-position of the sources (in m)<br> Ms magnetization of the sources (in A/m) profiles.txt<br> Localization of the simulated acquisition profiles<br> xx x-position of the data<br> yy y-position of the data<br> zz z-position of the data eqsources.txt<br> Localization and magnetization of the equivalent sources<br> xdeq x-position of the sources (in m)<br> ydeq y-position of the sources (in m)<br> zdeq z-position of the sources (in m)<br> JJ magnetization of the sources (in A/m) [1] Gavazzi, B., Bertrand, L., Munschy, M., Mercier de Lépinay, J., Diraison, M. & Géraud, Y. (submitted). On the use of aeromagnetism for geological interpretation part I: comparison of scalar and vector magnetometers for aeromagnetic surveys and an equivalent source interpolator for combining, gridding and transform fixed altitude and draping datasets, Journal of Geophysical Research: Solid Earth.